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Unacylated ghrelin promotes 
adipogenesis in rodent bone 
marrow via ghrelin O-acyl 
transferase and GHS-R1a activity: 
evidence for target cell-induced 
acylation
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Despite being unable to activate the cognate ghrelin receptor (GHS-R), unacylated ghrelin (UAG) 
possesses a unique activity spectrum that includes promoting bone marrow adipogenesis. Since a 
receptor mediating this action has not been identified, we re-appraised the potential interaction of UAG 
with GHS-R in the regulation of bone marrow adiposity. Surprisingly, the adipogenic effects of intra-
bone marrow (ibm)-infused acylated ghrelin (AG) and UAG were abolished in male GHS-R-null mice. 
Gas chromatography showed that isolated tibial marrow adipocytes contain the medium-chain fatty 
acids utilised in the acylation of UAG, including octanoic acid. Additionally, immunohistochemistry and 
immunogold electron microscopy revealed that tibial marrow adipocytes show prominent expression 
of the UAG-activating enzyme ghrelin O-acyl transferase (GOAT), which is located in the membranes 
of lipid trafficking vesicles and in the plasma membrane. Finally, the adipogenic effect of ibm-infused 
UAG was completely abolished in GOAT-KO mice. Thus, the adipogenic action of exogenous UAG in 
tibial marrow is dependent upon acylation by GOAT and activation of GHS-R. This suggests that UAG is 
subject to target cell-mediated activation – a novel mechanism for manipulating hormone activity.
Since its discovery1, the gastric hormone ghrelin has become established as a key player in the team of hormones 
co-ordinating central and peripheral processes with nutritional status2–4. Ghrelin is functionally unique, being 
the only identified peripheral signal of insufficient energy intake5 that promotes feeding behaviour6,7. However, 
ghrelin is also structurally unique, requiring post-translational acylation of the third (serine) residue to enable it 
to bind to and activate its cognate receptor, the growth hormone secretagogue receptor, GHS-R1a1,8. This modifi-
cation is accomplished by the action of ghrelin O-acyl transferase (GOAT), a member of the membrane-bound 
O-acyl transferase (MBOAT) family of enzymes9,10.
Despite these landmark discoveries, one major aspect of ghrelin physiology remains unresolved: the mech-
anism of action of unacylated ghrelin (UAG), the predominant form of the hormone in the circulation11. 
Although lack of acylation precludes the binding of UAG to GHS-R1a1 and prevents subsequent receptor acti-
vation8,11, UAG possesses a distinct profile of biological actions. For example, like acylated ghrelin (AG), UAG 
suppresses post-pubertal gonadotrophin secretion12,13, reduces gastric emptying14 and promotes bone marrow 
adipogenesis15. However, unlike AG, UAG does not stimulate GH secretion1, and may even suppress skeletal 
growth16. Although controversial17, the majority of studies report that, unlike AG, UAG does not promote feeding 
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behaviour14,16 or increase intra-abdominal fat mass18. This evidence has led several groups to speculate that UAG 
may exert this unique profile of actions via a novel receptor15,19,20, but no candidate receptors have emerged21.
We have, therefore, tested an alternative hypothesis, viz that the actions of UAG are mediated by GHS-R1a 
after local acylation by GOAT. We have utilised a wide range of experimental approaches to test this hypothesis, 
examining the effect of UAG on marrow adiposity in rodents. Marrow adipocytes are particularly well suited for 
this study because they can be treated in vivo in isolation from systemic influences15,22, they respond equally to 
AG and UAG15 and can be quantified readily in excised bone. Our results suggest a novel endocrine mechanism 
of target cell-mediated transacylation.
Results
Study 1: The effect of an ibm ghrelin/UAG infusion on marrow adiposity in GHS-R-null mice. 
To investigate whether the adipogenic activity of AG and UAG in tibial marrow is mediated by GHS-R, we per-
formed an ibm infusion of these two peptides in wild-type (WT) and loxTB-GHS-R (GHS-R-null) littermate 
mice. This approach revealed that infusion of AG or UAG had no significant effect on circulating ghrelin (total) 
in either WT or GHS-R-null mice (Fig. 1A). Similarly, although GHS-R-null mice showed a 3–4% reduction in 
tibial length (P < 0.001; Fig. 1B), neither AG nor UAG treatment had any effect on either tibial length (Fig. 1B) 
or tibial epiphyseal plate width (EPW; Fig. 1C). However, AG and UAG increased adipocyte number in WT mice 
by 90% (P = 0.0003; Fig. 1E) and 68% (P = 0.0128; Fig. 1E) respectively, though this only resulted in a significant 
elevation in overall adiposity in UAG-treated mice (116% increase, P = 0.0196; Fig. 1D). Mean adipocyte size was 
Figure 1. The adipogenic effect of AG and UAG is abolished in GHS-R-null mice. Quantification of 
circulating ghrelin (total) (A), tibial length (B), tibial epiphyseal plate width (EPW; C), total adiposity  
(D), adipocyte number (E) mean adipocyte size (F) and adipocyte size frequency (G,H) in mid-diaphyseal 
tibial marrow in male WT and loxTB-GHS-R mice receiving a 1-week intra-bone marrow infusion of vehicle 
(0.5 μ l/hr), AG (720 ng/day) or UAG (720 ng/day). Values shown are mean ± SEM (n = 4 (vehicle), 5 (UAG) & 
6 (AG)) with statistical comparisons performed by 1-way ANOVA and Bonferonni’s selected pairs post hoc test 
(*P < 0.05; ***P < 0.001 vs WT/vehicle-treated; ††P < 0.01 vs WT/AG-treated; • P < 0.05 vs WT/UAG-treated).
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not significantly affected by either treatment in WT mice (Fig. 1F), but spectral analysis revealed that AG induced 
an increase in the population of smaller (75–125 μ m2) adipocytes (P < 0.05; Fig. 1G). Although vehicle-treated 
GHS-R-null mice showed an 83% elevation in marrow adipocyte number in comparison to vehicle-treated WT 
mice (P < 0.001; Fig. 1E), neither AG nor UAG had any effect on any of the parameters of marrow adiposity in 
these animals (Fig. 1D–F,H). Indeed, the adipocyte size spectra were virtually super-imposable with that in vehi-
cle-treated GHS-R-null mice (Fig. 1H).
Study 2: Substrate availability in tibial bone marrow adipocytes. Given that UAG cannot bind to 
or activate GHS-R, study 1 suggests that the adipogenic action of UAG may depend upon prior conversion to AG, 
a process requiring the presence of appropriate medium-chain fatty acid substrates. To investigate whether mar-
row adipocytes contain the appropriate medium-chain fatty acids, we performed gas chromatography on lipid 
extracted from isolated rat tibial marrow adipocytes. These cells contain detectable levels of C8:0 (octanoic acid), 
C10:0, C12:0, C12:1, C14:0, C14:1 and C15:0, with C14:0 being the most abundant and octanoic acid constituting 
1.5% of total medium-chain fatty acid content (Fig. 2A and B).
Study 3: Visualisation of GOAT expression in tibial bone marrow. Given the presence of the appro-
priate medium-chain fatty acids, we used immunohistochemistry (IHC) to investigate whether marrow adipo-
cytes express the ghrelin-activating enzyme, GOAT. Our IHC approach, which revealed the expected visualisation 
of GOAT expression in the lower two thirds of the gastric pits (Fig. 3A and D), confirmed the GOAT was also 
expressed in mature marrow adipocytes (arrowheads in Fig. 3B) and in aggregations of smaller adjacent cells 
(arrows in Fig. 3B). Smears of lipid-containing rat marrow cells also showed marked GOAT expression (Fig. 3C). 
Double fluorescence IHC demonstrated that stomach expressed GOAT but not the adipogenic biomarker 
PPARγ (Fig. 3D–F). In contrast, UAG-insensitive retroperitoneal adipocytes expressed PPARγ but not GOAT 
(Fig. 3G–I), whereas isolated rat marrow adipocytes expressed both PPARγ and GOAT (Fig. 3J–L).
Study 4: Sub-cellular distribution of GOAT expression in tibial bone marrow adipocytes. We 
subsequently used immunogold electron microscopy to characterize the subcellular distribution of GOAT. In the 
neuroendocrine cells of the stomach, GOAT was expressed in the cytoplasm (arrows) and in association with the 
membrane of electron-translucent trafficking vesicles (arrowheads; Fig. 4B). Similarly, in the tibial marrow adipo-
cytes, GOAT immunoreactivity was identified in the cytoplasm (arrows) and in the membrane of both large and 
small lipid-trafficking vesicles (white arrowheads; Fig. 4D & F). In addition, immunogold labelling for GOAT was 
clearly present in the plasma membrane of the marrow adipocytes (black arrowheads; Fig. 4D and F).
Study 5: The effect of an ibm UAG infusion on marrow adiposity in GOAT-KO mice. Given 
the presence of the elements required for the acylation of UAG, we investigated whether the adipogenic effect 
of UAG in vivo is dependent upon GOAT, by treating GOAT-KO mice with a 1-week ibm infusion of UAG. 
Although halved, mean circulating ghrelin in UAG-treated WT mice was not significantly different from 
that in vehicle-treated WTs (Fig. 5A). Deletion of GOAT alone had no effect on circulating ghrelin (Fig. 5A). 
However, although unaffected by UAG treatment, circulating ghrelin in GOAT-KO mice was three times that in 
UAG-infused WT mice (P < 0.001; Fig. 5A). Similarly, tibial length was unaffected in GOAT-KO mice and, as in 
study 1, ibm infusion of UAG had no statistically significant effect on either tibial length or EPW (Fig. 5B and C). 
The effect of UAG treatment in WT mice was also similar to that seen in study 1 above (Fig. 1D–F), adipocyte 
number being doubled (P = 0.0152; Fig. 5E), without significantly affecting mean adipocyte size or overall adipos-
ity (Fig. 5F and D). This increase in adipocyte number was particularly prevalent in smaller adipocytes (Fig. 5G). 
In contrast, UAG had no effect on any of the parameters of marrow adiposity in GOAT-KO mice (Fig. 5D–F). 
Interestingly, in comparison to WT mice, vehicle-treated GOAT-KO mice showed a significant increase in the 
population of small adipocytes in tibial marrow (Fig. 5E,G and H).
Figure 2. Tibial bone marrow adipocytes contain medium-chain fatty acids. Gas chromatography was used 
to generate a chromatogram of medium-chain fatty acids in isolated rat tibial marrow adipocytes (A) and the 
relative proportion of specific medium-chain fatty acids (B).
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Discussion
UAG, the predominant form of ghrelin in the circulation, has been shown to exert a distinct profile of activities, 
but the mechanism of action of this hormone has remained enigmatic; an enigma exemplified by the adipogenic 
action of UAG in bone marrow. Like AG, UAG promotes marrow adipogenesis, and while it was assumed that 
this represented evidence of a GHS-R-independent action of UAG and possibly AG15, evidence for an alternative 
receptor mediating this action has remained elusive. We have now re-examined this phenomenon and the data 
we present here support the surprising hypothesis that the adipogenic action of UAG is dependent upon both 
GHS-R, the receptor to which it does not usually bind8,11, and the acylating activity of GOAT.
Using our miniaturised intra-bone marrow infusion strategy, we have demonstrated that the adipogenic 
activity of AG and UAG previously seen in rats15 was replicated in mice. However, we were surprised to find 
that the adipogenic activity of both forms of ghrelin was abolished in mice in which transcription of GHS-R is 
blocked. Since, the absence of the post-translational addition of an acyl side-chain precludes the binding of UAG 
to GHS-R1,8,11, we investigated the possibility that UAG could be acylated in the bone marrow milieu. Fatty acid 
profiling in isolated tibial marrow adipocytes revealed that these lipid-storing cells contain a range of detectable 
medium-chain fatty acids, including octanoic acid, the principle substrate for the activation of UAG23. It should 
be noted that while UAG can also be acylated with C10:0, C12:0, and C14:023,24, all of which are present in mar-
row adipocytes, icv injections of C12:0- and C14:0-AG are effective in elevating fat mass24, while C10:0-AG is as 
effective as octanoylated ghrelin in promoting GH secretion23. Thus, although we have not quantified the relative 
Figure 3. Tibial marrow adipocytes express GOAT. Visualization of GOAT expression using DAB (A–C) and 
fluorescence (D–L) IHC in stomach (A,D–F), retroperitoneal WAT (G–I) tibial bone marrow (B) and lipid-
containing tibial bone marrow cells (C,J–L). In DAB images GOAT expression is shown in brown (Arrowheads 
(B) show GOAT-positive adipocytes and arrows show adjacent smaller cells). Fluorescent images (D–L) show 
nuclei stained with DAPI (blue), GOAT expression in red (D,G,J), PPARγ expression in green (E,H,K) and co-
expression of GOAT and PPARγ in yellow in merged images (F,I,L). Scale bar: 50 μ m (A,B,D–I), 25 μ m (C,J–L); 
Lu stomach lumen.
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utilisation of these medium-chain fatty acids in the activation of UAG in bone marrow, the substrate required for 
acylation is clearly present.
Given the presence of these medium-chain fatty acids, we developed an immunohistochemical approach 
for visualising the presence of GOAT in marrow adipocytes. This revealed co-localisation of GOAT with the 
adipocyte-specific marker, PPARγ in marrow adipocyte smears and prominent expression of GOAT in the aggre-
gations of cells surrounding lipid-containing adipocytes. Whether these smaller cells represent pre-adipocytes or 
earlier stages in the differentiation process remains to be determined. This study clearly adds another tissue to the 
selective list of tissues now known to express GOAT, which includes the stomach, hypothalamus and pituitary, 
but not the pancreas, liver, kidney, spleen, heart, skeletal muscle, lung or WAT25–27, the latter being confirmed in 
the present study.
Since we have shown that these cells respond to exogenous UAG, we used the same primary antibody to char-
acterise the sub-cellular localisation of GOAT with immunogold electron microscopy. This revealed that although 
some GOAT immunoreactivity was located in the cytoplasm, the majority was associated with membrane struc-
tures, as would be expected for a member of the MBOAT family9. Its presence in the membrane of lipid trafficking 
vesicles suggests a role for GOAT in the regulation of lipid storage and release, whereas its presence in the plasma 
membrane provides circumstantial evidence that GOAT may enable marrow adipocytes to activate and subse-
quently respond to exogenous UAG.
We believe our data to represent the first description of the sub-cellular localisation of GOAT, even in the 
stomach. GOAT has previously been located in membranes of the endoplasmic reticulum (ER)28 where it may 
Figure 4. GOAT is expressed in intracellular and plasma membranes of tibial marrow adipocytes. Low 
magnification electron micrographs showing the general appearance of neuroendocrine cells in rat stomach 
(A) and bone marrow adipocytes (C,E). High magnification electron micrographs with immunogold labelling 
of GOAT in stomach (B) and tibial marrow adipocytes (D,F) showing expression in the cytoplasm (arrows), 
trafficking vesicles (open arrowheads) and plasma membrane (closed arrowheads).
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transport acyl-coA from the cytosol to the ER lumen9, and regulate the balance between AG and UAG secretion. 
Although assumed to be associated with the secretory pathway, our study indicates that GOAT expression in 
gastric neuroendocrine cells appears to be most prominent in the membrane of electron-translucent trafficking 
vesicles rather than the electron-dense secretory granules. Since cultured cells require the addition of n-octanoic 
acid to the medium for efficient AG production29, it is possible that these trafficking vesicles provide the substrate 
necessary for the acylating action of GOAT.
To investigate whether the presence of GOAT is essential for the adipogenic activity of UAG, we repeated 
our tibial marrow infusion experiment in GOAT-KO mice. The UAG-induced doubling of marrow adipocyte 
number seen in WT mice was abolished by the deletion of GOAT. Thus, in addition to the previous evidence 
that co-transfection of endocrine and non-endocrine cells with GOAT and pre-proghrelin cDNAs results in 
detectable AG production9,10, we have demonstrated that the adipogenic effect of exogenous UAG in tibial bone 
marrow is dependent upon the function of GOAT and the presence of GHS-R. Whether marrow adipocytes 
or pre-adipocytes express pre-proghrelin themselves, enabling acylation of intra-cellular UAG, or whether the 
effects reported here in males are observable in females, remains to be determined.
A couple of alternative mechanistic explanations should be considered. Firstly, it is possible that a lack of AG 
feedback in GHS-R-null and GOAT-KO mice could result in an elevation in UAG production and a maximal adi-
pogenic response in tibial marrow via the unidentified receptor. The doubling of the marrow adipocyte popula-
tion in GHS-R-null and GOAT-KO mice, which is due to the increased prevalence of smaller adipocytes, appears 
to support this suggestion and could potentially mask any additional activity of exogenous UAG. However, it 
Figure 5. The adipogenic effect of UAG is abolished in GOAT-KO mice. Quantification of circulating ghrelin 
(total) (A), tibial length (B), tibial epiphyseal plate width (EPW; C), total adiposity (D), adipocyte number (E) 
and mean adipocyte size (F) in mid-diaphyseal tibial marrow in male WT and GOAT-KO mice receiving a 
1-week intra-bone marrow infusion of vehicle (0.5 μ l/hr) or UAG (720 ng/day). Comparison of the distribution 
profiles of adipocyte size between vehicle- and UAG-treated WT (G), and vehicle- and UAG-treated GOAT−/− 
mice (H) are shown with adipocytes larger than 1000 μ m2 presented as inset histograms. Values shown are 
mean ± SEM (n = 5 (vehicle- and UAG-treated WT, vehicle-treated GOAT−/−) & 6 (UAG-treated GOAT−/−)), 
with statistical comparisons performed by 1-way ANOVA and Bonferonni’s selected pairs post hoc test (A–C) or 
Student’s t-test (G,H) (*P < 0.05; **P < 0.01 vs vehicle-treated WT).
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should be noted that circulating (total) ghrelin, the majority of which is UAG11, was not elevated in either the 
loxTB-GHS-R or GOAT-KO mice in this study. These data confirm previous reports that neither AG nor UAG are 
elevated in loxTB-GHS-R mice30,31 and that GOAT-KO mice display levels of circulating UAG within the physio-
logical range10. Thus, although we have not quantified ghrelin production within the tibial marrow, we think this 
explanation to be unlikely.
In this context it should be noted that while GHS-R-null mice show relatively normal circulating IGF-132, 
GOAT-KO mice show elevated circulating IGF-1 in conjunction with reduced GH secretion33. Since marrow 
adipocytes are exquisitely sensitive to GH34, a modest reduction in GH could explain the increase in adipocyte 
number in both of these models. That said, the elevated marrow adiposity in the profoundly GH-deficient dw/dw 
rat remains remarkably sensitive to the adipogenic effects of both AG and UAG15.
Secondly, although it was initially thought that UAG does not bind to GHS-R, subsequent studies have 
demonstrated that this is not the full picture. Although UAG has been shown to antagonize the metabolic effects 
of AG35 it acts as an agonist of GHS-R1a but with a 1000-fold lower efficacy than AG36. This latter action appears 
to be dependent, in part, upon the electrostatic attraction of the ligand to the receptor and its associated plasma 
membrane37. However, given that AG and UAG are equipotent in stimulating marrow adipogenesis and this 
action is entirely dependent upon the presence of GOAT, any contribution of direct agonist activity of UAG in the 
current study is likely to be negligible.
Thirdly, recent evidence has demonstrated that GHS-R1a forms heterodimers with a wide array of 
G-protein-coupled receptors, even in the absence of AG38. Thus, the absence of an adipogenic effect of UAG 
in GHSR-null mice could be explained by a lack of dimer formation with the unidentified receptor for UAG. 
However, our demonstration of the presence and necessity of GOAT in this action, suggests that while we cannot 
completely exclude the possibility that UAG may activate an unidentified dimer partner, the weight of evidence 
seems to favour a direct action via GHS-R1a.
In the context of the bone marrow, the adipocytes are emerging as more than just a space filler, as originally 
thought. Secreting high levels of leptin39, these cells are able to influence the bone microenvironment and exert an 
impact on the microarchitecture and mechanical integrity of bone22. Our data indicate that the balance between 
bone forming and fat storing cells in the marrow is likely to be nutritionally regulated, and that AG and UAG may 
defend marrow fat from utilisation during starvation40. However, it is also becoming clear that the relationship 
between marrow adipocytes and bone integrity in different bone types is not uniform41.
Although our evidence that the adipogenic action of UAG in bone marrow is dependent upon acylation and 
activation of GHS-R, this is clearly not the case for all of the actions of UAG. For example, whilst deletion of 
GHS-R abolishes the effect of icv UAG on fat mass and hyperinsulinaemia42, it fails to prevent the vasodilatory 
effects of UAG43, the UAG-induced impairment of fasting-induced skeletal muscle atrophy44 and skeletal muscle 
regeneration45, or the effects of UAG on genes involved in glucose and lipid metabolism in fat, muscle and liver46.
Indeed, our data lends weight to the emerging evidence that marrow adipocytes are not representative of 
extra-medullary adipocytes. For example, we have previously shown that while retroperitoneal WAT is the most 
sensitive of the intra-abdominal depots to AG exposure15, it fails to respond to iv infusions of UAG18. Our current 
evidence suggests that this insensitivity of abdominal WAT may be due to a lack of GOAT expression, because 
deletion of GHS-R abolishes the positive influence of AG on abdominal WAT mass, thereby providing functional 
evidence that abdominal adipocytes express GHS-R18.
However, we believe our data to have wider significance. Not only does our evidence confirm that UAG is 
a significant hormone in its own right, but it implies that target cells for this hormone are able to regulate their 
response by manipulating the activity of incoming UAG. Our hypothesis is that expression of GOAT in the 
plasma membrane of cells containing substrate for acylation can add the required sidechain to exogenous UAG, 
thereby enabling activation of GHS-R (Fig. 6). In this model GOAT, would activate UAG in a reciprocal fashion 
Figure 6. The transacylation of exogenous UAG in tibial marrow adipocytes. Intra-bone marrow (ibm) 
infusions of ghrelin and UAG induce adipogenesis in tibial marrow of mice. 2. Ghrelin O-acyl transferase 
(GOAT) in the plasma membrane of marrow adipocytes utilises octanoic acid (C8:0) and other medium-chain 
fatty acids from within marrow adipocytes to acylate exogenous UAG. 3. Acylation of UAG to ghrelin permits 
activation of GHS-R1a.
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to the role of deiodinase 2, which activates T4 by the removal of an iodine. This novel mechanism may be impor-
tant in tissues known to express GOAT, including in the stomach, enteroendocrine cells of the intestine, anterior 
pituitary, pancreatic islets, thyroid, parathyroid25,27,47 and hypothalamus. Indeed, in the hypothalamus, where the 
uptake of UAG and AG are differentially controlled48, region-specific expression of GOAT may enable individual 
nuclei to activate GHS-R in response to UAG, but not to AG. In addition, the nutritional regulation of GOAT 
expression in the hypothalamus provides another layer of mechanistic complexity27.
In summary, we have demonstrated that in tibial bone marrow, UAG promotes adipogenesis by a mechanism 
involving GOAT-mediated acylation and the activation of GHS-R. Thus, access of UAG to the site of action, 
coupled with the presence of GOAT on the plasma membrane and the expression of GHS-R will determine the 
unique activity profile of this important metabolic hormone.
Methods
Animals. The animal procedures described, including those involving genetically modified animals, were con-
ducted in accordance with the UK Animals (Scientific Procedures) Act, 1986 and the ARRIVE Guidelines, and 
were specifically approved by ethical review at Cardiff University. Male rats (Sprague Dawley (SD) (Harlan UK 
Ltd., Bicester, Oxon, UK); Studies 2, 3 & 4) and mice (Studies 1 & 5) used were housed under conditions of 14 h 
light/10 h dark (lights on at 05.00 h) in the animal facility at Cardiff University, with food (Harlan Teklad Rodent 
Maintenance Diet containing 4.9% oil and 14.2% protein) and water available ad libitum. loxTB-GHS-R mice 
and their wild type (WT; C57Bl6) littermate controls32 were bred from heterozygous x heterozygous matings in 
the animal facility at Cardiff University from founder stock imported from the University of Texas Southwestern 
Medical Center (Dallas, TX) (Study 1). Homozygous GOAT-KO mice and their WT (C57Bl6) controls10 were 
imported from Taconic Farms (Hudson, NY) (Study 5).
Study 1: Effect of an ibm ghrelin/UAG infusion on marrow adiposity in GHS-R-null mice. 
9-month old male loxTB-GHS-R (GHS-R-null) mice (31.8 ± 0.8 g (n = 16)) and age-matched male WT littermate 
controls (34.4 ± 0.6 g (n = 13); P < 0.01) were prepared with right tibial intra-bone marrow (ibm) catheters con-
nected to osmotic minipumps (Alzet model 1007D) primed to deliver vehicle (sterile isotonic saline containing 
BSA (1 mg/ml) and heparin (5 U/ml) at 0.5 μ l/h), AG (720 ng/day) or UAG (720 ng/day) for 7 days. This approach, 
performed under isoflurane anaesthesia, was a miniaturised version of the technique previously used in rats15,22. 
This dose of ghrelin was calculated to produced a mid-range increase in bone marrow adiposity based upon on 
a dose-response curve for intravenously (iv) infused AG constructed in mice (Supplementary Figure 1) and the 
difference in effectiveness of iv and ibm infusions previously reported in rats15. At term, the mice were weighed, 
re-anaesthetized with isofluorane and decapitated. Plasma samples were separated from trunk blood and stored 
at − 20 °C for subsequent determination of circulating ghrelin. Right tibiae were dissected, the length measured 
using a hand-held micrometer and stored for subsequent quantification of marrow adiposity and EPW.
Study 2: Quantification of lipid content of marrow adipocytes. To determine whether marrow adi-
pocytes contain the required substrate for octanoylation, the medium-chain fatty acid profile was determined in 
isolated rat marrow adipocytes. Three male SD rats (24 weeks-old; 424–474 g) were concussed and killed by cervical 
Figure 7. Validation of GOAT IHC in rat stomach. Fluorescent IHC for GOAT in 12 μ m cryostat sections 
of rat stomach either with (A) or without (B) inclusion of the primary rabbit anti-GOAT antibody (1:1000 
dilution), or with pre-absorption of the primary antibody (1:1000 dilution) with GOAT peptide (10 μ M; 
C). Images D-G show the effect of serial dilutions of the primary antibody (D: 1:1000; E: 1:2000; F: 1:4000; 
G: 1:8000). Nuclei were stained with DAPI (blue), with GOAT expression seen in red. Scale bars: 50 μ m; Lu 
stomach lumen.
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dislocation and left tibiae excised. After removal of the distal epiphyses, the marrow contents were centrifuged 
into sterile isotonic saline and the adipocytes aspirated from the aqueous surface and pooled. Lipid contents were 
extracted using the Kates method49 and fatty acid methyl esters prepared by transmethylation with 2.5% H2SO4 
in HPLC-grade methanol/toluene (2:1) at 70 °C for 2 h. A known amount of pentadecanoate (15:0) was added as 
an internal standard to enable subsequent fatty acid quantification. A Clarus 500 gas chromatograph with a flame 
ionizing detector and fitted with a 30 m × 0.25 mm internal diameter capillary column (Perkin Elmer Elite 225) was 
used for fatty acid identification. Peaks were integrated using TotalChrom software (Perkin-Elmer, version 6.2.1).
Study 3: Visualisation of GOAT expression in tibial bone marrow. An IHC approach was developed 
for visualizing GOAT expression in stomach (12 μ m cryostat sections of fresh frozen tissue taken from the greater 
curvature of the corpus and stored at − 20 °C until use), tibiae (7 μ m longitudinal sections of decalcified, paraffin 
embedded tibiae, including mid-cortical marrow), tibial marrow adipocyte smears (adipocytes obtained as above 
(study 2) and smeared onto poly-L-lysine-coated microscope slides and stored at − 20 °C) and retroperitoneal 
WAT (12 μ m cryostat sections of fresh frozen tissue stored at − 20 °C until use). These tissues were harvested from 
rats in study 2.
Stomach sections were fixed in 4% paraformaldehyde (in PBS), subjected to antigen recovery (incubation in 
10 mM sodium citrate in 0.05% Tween 20 at 60 °C for 1 hr), permeabilized in methanol, blocked in 10% normal 
goat serum (NGS) and incubated overnight with a rabbit anti-GOAT primary antibody; Table 1. Incubation 
with a fluorescent secondary antibody (1:500; Cy3-conjugated sheep anti-rabbit IgG) produced the expected47 
red fluorescence for GOAT in the mid to lower portions of the gastric pits (Fig. 7A). The fluorescent signal was 
dependent upon primary antibody dilution (Fig. 7D–G) and was abolished by omission of the primary antibody 
(Fig. 7B) or pre-incubation of the primary antibody (1:1000 dilution) with rat GOAT peptide (10 μ M; Cat no. 
032-12; Phoenix Europe GmbH, Karlsruhe, Germany) (Fig. 7C). A 1:2000 dilution of the primary antibody was 
used in subsequent experiments.
Since paraffin-embedded tibial sections yielded significant autofluorescence, non-fluorescent IHC was used 
for these samples. Tibial marrow sections were de-waxed, and, together with stomach sections and tibial mar-
row adipocyte smears were treated as above up to and including incubation with the primary antibody, except 
that permeabilization with methanol was replaced with treatment with hydrogen peroxide (0.3% in methanol). 
Sections were incubated with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody, stained 
with diaminobenzidine tetrahydrochloride (DAB) and counterstained with Meyer’s haematoxylin.
GOAT-positive cells in the marrow cell smears were identified by double fluorescence IHC for GOAT and 
PPARγ . The above IHC protocol was followed except that the primary antibody solution contained both rab-
bit anti-GOAT and mouse anti-human PPARγ (1:100 dilution; Cat No 419300; Invitrogen Corporation, 
Camarillo, CA; Table 1) and the secondary antibody solution contained both Cy3-linked sheep anti-rabbit and 
Alexa-fluor488-linked goat anti-mouse antibodies (1:500).
Study 4: Visualisation of the subcellular distribution of GOAT in tibial bone marrow adipocytes. 
The subcellular distribution of GOAT in marrow adipocytes was visualised by immunogold electron microscopy 
(EM). Isolated tibial marrow adipocytes were obtained as in study 2 from two 9 week-old male SD rats, centri-
fuged into sterile saline and aspirated into 2% glutaraldehyde (EM grade): 2% formaldehyde in 0.1 M phosphate 
buffer. After 5 mins cells were transferred into 10% fixative and stored at 4 °C prior to embedding. Cells and 
0.5 mm3 segments of stomach were prepared by a standard method50 in which segments were stained with ura-
nyl acetate (2% w/v in distilled water), dehydrated through methanol (70–100%) and embedded in LR Gold. 
Ultrathin sections (50–80 nm) were prepared using a Reichert ultracut S microtome and mounted on 200 mesh 
nickel grids. Ultrathin sections were incubated with rabbit anti-GOAT antibody (1:1000 in 0.1 M phosphate buffer 
containing 0.1% egg albumin) at room temperature for 2 h and with Protein A-15 nm gold complex (1:50) for 1 h. 
No non-specific labelling was observed in the absence of the primary antibody. After immunolabelling, sections 
were lightly counter-stained with lead citrate and uranyl acetate and examined with a JEOL transmission electron 
microscope, images being collected with a GATAN Orius camera.
Study 5: The effect of an ibm UAG infusion on marrow adiposity in GOAT-KO mice. To estab-
lish whether local GOAT expression determines the effectiveness of UAG, 9-month old male GOAT-KO mice 
(31.8 ± 0.9 g) and age-matched male WT littermate controls (34.0 ± 0.9 g; P = 0.054) were prepared with ibm 
catheters and osmotic minipumps primed to deliver either vehicle or UAG as in study 1. At term, the mice were 
Antigen
Host 
Species Manufacturer Cat #
Final 
Dilution
Primary Antibodies
Human GOAT Rabbit Phoenix Europe GmbH H-032-12 1:2000
Human PPARγ Mouse Invitrogen Corporation 419300 1:100
Secondary Antibodies (IHC)
Cy3-conjugated anti-rabbit IgG Sheep Sigma-Aldrich Company Ltd. C2306 1:500
Alexa-fluor488- anti-mouse Goat Life Technologies, USA A11001 1:500
Secondary Antibodies (Immunogold EM)
AU conjugate (Protein A 15 nm Gold) Rabbit British Biocell, Cardiff, UK EM.PAG15 1:50
Table 1.  Antibodies used for IHC and immunogold EM visualization of GOAT.
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weighed, re-anaesthetized with isofluorane and decapitated. Plasma samples separated from trunk blood were 
stored at − 20 °C for subsequent determination of circulating ghrelin and right tibiae were dissected as above for 
quantification of marrow adiposity.
Quantification of marrow adiposity and EPW. Marrow adiposity and EPW were quantified as previ-
ously described15. Briefly, tibiae were fixed, decalcified in EDTA and sectioned as in study 3, with sections stained 
with Masson’s Trichrome or Toluidine Blue for quantification of EPW and marrow adiposity respectively. Leica 
Q-Win was used to measure EPW under light microscopy. Adiposity was quantified using the method of Gevers 
et al.34. Digital images (1 × 186304 μ m2 field/section; 3 sections/tibia) were taken of mid-diaphyseal marrow with 
a Leica DFC300FX digital camera and a Leica DMLB microscope. Image J was used to quantify the degree of 
adiposity, adipocyte number and adipocyte size.
Quantification of circulating ghrelin. Circulating (total) ghrelin was quantified in terminal plasma sam-
ples from studies 1 and 5 using a rat/mouse Ghrelin (total) ELISA kit (EZRGRT-91K; Millipore, UK) as per the 
manufacturer’s instructions. Absorbance was measured using a POLARstar Omega plate reader (BMG Labtech, 
Cambridge, UK) and concentrations determined according to the manufacturer’s instructions (Intra-assay var-
iation: 10.96%).
Statistical analyses. Results are expressed as mean ± SEM (with the number of animals used per group 
indicated in the figure legends), and differences between groups compared by Student’s t-test or one-way ANOVA 
followed by Bonferroni’s (selected pairs) post-hoc test using GraphPad Prism, with p < 0.05 considered signifi-
cantly different.
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